Search
Montelukast
go.drugbank.com/drugs/DB00471ApprovedInvestigationalMontelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. … [L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled
Categories: Agents to Treat Airway DiseaseProducts: Nb-montelukast, N-FESS 10 MG FILM TABLET, 90 ADETFloxuridine
go.drugbank.com/drugs/DB00322ApprovedInvestigationalWhen administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. … An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution.
Diazoxide
go.drugbank.com/drugs/DB01119ApprovedInvestigational[A255647,L44612] It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity. … [A190372] When administered intravenously, diazoxide can be used to treat hypertensive emergencies;[L44622] however, this specific form of diazoxide is no longer available in the US.
Categories: Arteriolar Smooth Muscle, Agents Acting OnEbola Zaire vaccine (live, attenuated)
go.drugbank.com/drugs/DB15595ApprovedInvestigational[L10854] Ebola virus disease, formerly known as Ebola hemorrhagic fever, is a rare but severe and often deadly disease. … [L10854] By introducing the relatively inactive viral protein to the patient, the patient’s immune system learns to recognize and attack the virus if he or she is exposed to it in the future.
Ozanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigational[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. … It was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA on March 26, 2020.
Lemborexant
go.drugbank.com/drugs/DB11951ApprovedInvestigational[L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Hetacillin
go.drugbank.com/drugs/DB00739ApprovedVet approvedWithdrawnHetacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. … Hetacillin has been withdrawn from the market since it has been discovered that it has no therapeutic advantage compared to non-ester derivatives like ampicillin.
Carisoprodol
go.drugbank.com/drugs/DB00395ApprovedIn January 2012, this drug was classified as a Schedule IV substance under the controlled substances act in several US states due to alarming rates of abuse [A176062, A176077] despite having a low potential … This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with both aspirin and codeine [FDA label, F4060, F4069].
Synonyms: N-isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamateIsocarboxazid
go.drugbank.com/drugs/DB01247Approved[T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959.
Categories: Monoamine Oxidase Inhibitors, Non-Selective, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromePlazomicin
go.drugbank.com/drugs/DB12615ApprovedIt mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis [FDA Label]. … On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis.